NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 55 filers reported holding NUVALENT INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $350,273,609 | +9.0% | 7,619,613 | +0.0% | 0.03% | +11.1% |
Q2 2023 | $321,256,289 | -19.9% | 7,618,124 | -50.5% | 0.03% | +50.0% |
Q1 2023 | $401,286,324 | +76.8% | 15,380,848 | +101.9% | 0.02% | -21.7% |
Q4 2022 | $226,910,497 | +81.1% | 7,619,560 | +18.2% | 0.02% | +76.9% |
Q3 2022 | $125,323,000 | +43.7% | 6,446,671 | +0.2% | 0.01% | +44.4% |
Q2 2022 | $87,215,000 | -2.4% | 6,431,812 | -0.0% | 0.01% | +28.6% |
Q1 2022 | $89,346,000 | -25.7% | 6,432,387 | +0.1% | 0.01% | -22.2% |
Q4 2021 | $120,240,000 | -14.0% | 6,427,307 | 0.0% | 0.01% | -18.2% |
Q3 2021 | $139,875,000 | – | 6,427,307 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |